Agilent Technologies Inc., a spinout of Hewlett Packard, is the world’s premier measurement company and a leader in chemical analysis and measurement equipment. Agilent has entered into an option agreement for a nozzle technology developed by Dr. Uwe Weierstall, et.al. that produces nanoscale droplets from a virtual gas nozzle without clogging. Agilent is exploring the use of these nozzles in their analytic and diagnostic measuring equipment.
Advanced Tear Diagnostics, LLC, has exclusively licensed a patent portfolio for developing in vitro and in vivo diagnostics using tear fluid, saliva or blood for humans or companion animals. The company plans to develop a device that measures glucose levels in tears, which has the potential to replace current tests that require individuals with Type II diabetes to prick a finger every day to draw blood samples. The technology was developed by Dr. Jeffrey LaBelle et al. at ASU.
Curtiss Healthcare Inc., an ASU startup company, has licensed a platform technology employing attenuated Salmonella bacteria for the development of animal and human vaccines. The technology is based on a genetically engineered proprietary strain of Salmonella that is attenuated in its virulence and produces a robust immune response that is used as a vehicle for the introduction of a suitable antigen from a pathogenic microorganism (bacteria, viruses and fungi). The IP portfolio was created by Dr. Roy Curtiss et al. at ASU.
Rogers Corporation, a global leader in innovative materials for power electronics and antennas, has entered into a non-exclusive option agreement for commercializing a novel process for creating thin film ferrite material developed at ASU by Dr. William Petuskey. This cutting-edge production process is cost effective, low temperature and moldable to any plastic shape. Additionally, Rogers Corporation has also entered into a sponsored research agreement with the university to further develop this technology.